—With the initiation of ENLIGHTEN-Cirrhosis, pegozafermin is the first FGF21 analog to enter a Phase 3 trial in MASH patients...
Apellis received $375 million in funding at close, with ability to access an additional $100 millionMajority of initial proceeds used...
Conference Call and Webcast Today at 4:30 p.m. ETDevelopment Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive...
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission...
Takeda has completed two Phase 3 trials studying soticlestat as a treatment for Lennox-Gastaut syndrome and Dravet syndrome; topline data...
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...
The Company has also completed the GMP validation work allowing for the release of both MDMA dosage formatsVANCOUVER, British Columbia,...
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs built around two proprietary technologies – Cholesterol Efflux...
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase...
Best Quarterly Results in Company’s History from a Financial Perspective.EBITDA Improvements Driven by Record Revenues, Record Margins and Operational Efficiencies.Marketing...
Agreement includes the discovery and enhancement of targeted oncology drug targets and biomarkers, in addition to positioning existing compoundsDURHAM, N.C.,...
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members...
NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
– Company enrolls 85 patients with R/R NPM1-mutant AML in fewer than 16 months – – Topline data expected in...
PALO ALTO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...
Call Scheduled for Today, Tuesday, May 14, 2024 at 5:00 pm ETLITTLETON, Colo., May 14, 2024 (GLOBE NEWSWIRE) -- Vivos...
12-week treatment with Bexotegrast 160 mg resulted in reduction of total lung collagen as measured by PET imaging, compared to an...
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of...
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American...
Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024...